BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 8570116)

  • 1. Humoral anti-OV-TL 3 response after the intravenous administration of radiolabelled Fab' or F(ab')2 fragments in ovarian cancer patients.
    Tibben JG; Thomas CM; Massuger LF; Segers MF; Schijf CP; Corstens FH; Boerman OC
    Nucl Med Commun; 1995 Oct; 16(10):853-9. PubMed ID: 8570116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minor human antibody response to a mouse and chimeric monoclonal antibody after a single i.v. infusion in ovarian carcinoma patients: a comparison of five assays.
    Buist MR; Kenemans P; van Kamp GJ; Haisma HJ
    Cancer Immunol Immunother; 1995 Jan; 40(1):24-30. PubMed ID: 7828165
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pharmacokinetics, biodistribution and dosimetry of monoclonal antibodies OC125, OV-TL 3, and 139H2 as IgG and F(ab')2 fragments in experimental ovarian cancer.
    Molthoff CF; Pinedo HM; Schlüper HM; Nijman HW; Boven E
    Br J Cancer; 1992 May; 65(5):677-83. PubMed ID: 1586596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific and nonspecific immunoassays to detect HAMA after administration of indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibody to patients with ovarian cancer.
    Massuger LF; Thomas CM; Segers MF; Corstens FH; Verheijen RH; Kenemans P; Poels LG
    J Nucl Med; 1992 Nov; 33(11):1958-63. PubMed ID: 1432156
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human antibody response to the intravenous and intraperitoneal administration of the F(ab')2 fragment of the OC125 murine monoclonal antibody.
    Maher VE; Drukman SJ; Kinders RJ; Hunter RE; Jennings J; Brigham C; Stevens S; Griffin TW
    J Immunother (1991); 1992 Jan; 11(1):56-66. PubMed ID: 1734949
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.
    Glennie MJ; McBride HM; Worth AT; Stevenson GT
    J Immunol; 1987 Oct; 139(7):2367-75. PubMed ID: 2958547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biodistribution of iodine-125 and indium-111 labeled OV-TL 3 intact antibodies and F(ab')2 fragments in tumor-bearing athymic mice.
    Massuger LF; Boerman OC; Corstens FH; Verheijen RH; Claessens RA; Poels LG; van den Broek WJ; Kenemans P
    Anticancer Res; 1991; 11(6):2051-7. PubMed ID: 1776839
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-murine antibody response to mouse monoclonal antibodies in cancer patients.
    Sakahara H; Saga T; Onodera H; Yao Z; Nakamoto Y; Zhang M; Sato N; Nakada H; Yamashina I; Endo K; Konishi J
    Jpn J Cancer Res; 1997 Sep; 88(9):895-9. PubMed ID: 9369938
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The binding parameters of radiolabelled monoclonal F (ab')2 and Fab' fragments relative to immunoglobulin G in reactions with surface-bound antigens.
    Fjeld JG; Michaelsen TE; Nustad K
    Eur J Nucl Med; 1992; 19(6):402-8. PubMed ID: 1618231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumour detection and localization using 99Tcm-labelled OV-TL 3 Fab' in patients suspected of ovarian cancer.
    Tibben JG; Massuger LF; Claessens RA; Schijf CP; Pak KY; Strijk SP; Kenemans P; Corstens FH
    Nucl Med Commun; 1992 Dec; 13(12):885-93. PubMed ID: 1465272
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human anti-mouse antibody response in cancer patients following single low-dose injections of radiolabeled murine monoclonal antibodies.
    Dillman RO; Shawler DL; McCallister TJ; Halpern SE
    Cancer Biother; 1994; 9(1):17-28. PubMed ID: 7812354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of human anti-murine antibody (HAMA) response in patients.
    Tjandra JJ; Ramadi L; McKenzie IF
    Immunol Cell Biol; 1990 Dec; 68 ( Pt 6)():367-76. PubMed ID: 1711007
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution of monoclonal IgG1, F(ab')2, and Fab' in mice after intravenous injection. Comparison between anti-B cell (anti-Lyb8.2) and irrelevant (MOPC-21) antibodies.
    Holton OD; Black CD; Parker RJ; Covell DG; Barbet J; Sieber SM; Talley MJ; Weinstein JN
    J Immunol; 1987 Nov; 139(9):3041-9. PubMed ID: 3499463
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Site-specific conjugation of bifunctional chelator BAT to mouse IgG1 Fab' fragment.
    Li J; Wang XH; Wang XM; Chen ZL
    Acta Pharmacol Sin; 2006 Feb; 27(2):237-41. PubMed ID: 16412275
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunoscintigraphy of ovarian cancer with indium-111-labeled OV-TL 3 F(ab')2 monoclonal antibody.
    Massuger LF; Kenemans P; Claessens RA; Verheijen RH; Schijf CP; Strijk SP; Poels LG; van Hoesel RG; Corstens FH
    J Nucl Med; 1990 Nov; 31(11):1802-10. PubMed ID: 2230993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts.
    Lütje S; van Rij CM; Franssen GM; Fracasso G; Helfrich W; Eek A; Oyen WJ; Colombatti M; Boerman OC
    Contrast Media Mol Imaging; 2015; 10(1):28-36. PubMed ID: 24764162
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of ELISAs for quantification of HMFG1-specific human anti-mouse IgG and IgM antibodies.
    Oei AL; Boerman OC; Geurts-Moespot A; van Eerd JE; van Tienoven D; Courtenay-Luck N; Thomas CM; Massuger LF; Sweep FC
    Int J Biol Markers; 2007; 22(3):167-71. PubMed ID: 17922458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibody Fab' fragment cross-linking using equilibrium transfer alkylation reagents. A strategy for site-specific conjugation of diagnostic and therapeutic agents with F(ab')2 fragments.
    Wilbur DS; Stray JE; Hamlin DK; Curtis DK; Vessella RL
    Bioconjug Chem; 1994; 5(3):220-35. PubMed ID: 7918742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quantitation of IgG and IgM human anti-mouse antibodies (HAMA) interference in CA 125 measurements using affinity chromatography.
    Koper NP; Thomas CM; Massuger LF; Segers MF; Olthaar AJ; Verbeek AL
    Clin Chem Lab Med; 1998 Jan; 36(1):23-8. PubMed ID: 9594082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor targeting properties of indium-111 labeled genetically engineered Fab' and F(ab')2 constructs of chimeric tumor necrosis treatment (chTNT)-3 antibody.
    Khawli LA; Alauddin MM; Hu P; Epstein AL
    Cancer Biother Radiopharm; 2003 Dec; 18(6):931-40. PubMed ID: 14969605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.